Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Oncotelic Therapeutics, Inc. | Financial_Report.xls |
| 10-K - FORM 10-K - Oncotelic Therapeutics, Inc. | d276228d10k.htm |
| EX-23.1 - CONSENT OF ERNST & YOUNG LLP - Oncotelic Therapeutics, Inc. | d276228dex231.htm |
| EX-10.37 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT - Oncotelic Therapeutics, Inc. | d276228dex1037.htm |
| EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) - Oncotelic Therapeutics, Inc. | d276228dex311.htm |
| EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) - Oncotelic Therapeutics, Inc. | d276228dex312.htm |
Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of OXiGENE, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Annual Report for the year ended December 31, 2011 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Dated: March 28, 2012 | /s/ Peter J. Langecker Peter J. Langecker, Chief Executive Officer |
|||
| Dated: March 28, 2012 | /s/ James B. Murphy James B. Murphy, Chief Financial Officer |
|||